Peptidyl-tRNA hydrolase 2 (PTRH2) is primarily a mitochondrial protein and is mainly expressed in the developing brain. It contains an amino-terminal signaling sequence which is involved in its mitochondrial localization.
Synonyms: Anti-BIT1; Anti-CFAP37; Anti-CGI-147; Anti-PTH2
Storage: -20C
Application: Anti-PTRH2 antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org). Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Peptidyl-tRNA hydrolase 2 (PTRH2) takes part in integrin-mediated cell survival and apoptosis signaling. PTRH2 prevents the peptidyl-tRNAs from accumulating once they dissociate from the ribosomes. After the integrin-mediated cell attachment, it interacts with focal adhesion kinase (FAK) and induces cell survival. It has an important role in anoikis, cell death due to loss of cell attachment to the extra cellular matrix. When this occurs, PTRH2 moves from mitochondria into the cytosol. It then forms a complex with the transcriptional regulator amino-terminal enhancer of split (AES) to mediate apoptosis. PTRH2 suppresses the phosphorylation of extracellular signal-regulated kinase (ERK). It regulates nuclear factor ?ß (NF?ß) and ERK signaling. Mutations in the gene have been associated with an infantile multisystem neurologic, endocrine and pancreatic disease (IMNEPD).
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC